Several studies have suggested a variety of biological factors (anti-TNF-α, anti-integrins, or anti-ILs) and small molecules (tofacitinib, a non-selective Janus kinase (JAK) inhibitor) as the therapeutic targets for the treatment of IBD. Here, TNF is linked to inflammatory bowel disease.